195 related articles for article (PubMed ID: 27846142)
1. Predictors of Early Mortality After Surgical Resection of Pancreatic Adenocarcinoma in the Era of Neoadjuvant Treatment.
Nipp RD; Zanconato A; Zheng H; Ferrone CR; Lillemoe KD; Wo JY; Hong TS; Clark JW; Ryan DP; Fernández-Del Castillo C
Pancreas; 2017 Feb; 46(2):183-189. PubMed ID: 27846142
[TBL] [Abstract][Full Text] [Related]
2. Increased neutrophil-to-lymphocyte ratio after neoadjuvant therapy is associated with worse survival after resection of borderline resectable pancreatic ductal adenocarcinoma.
Glazer ES; Rashid OM; Pimiento JM; Hodul PJ; Malafa MP
Surgery; 2016 Nov; 160(5):1288-1293. PubMed ID: 27450715
[TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant therapy offers longer survival than upfront surgery for poorly differentiated and higher stage pancreatic cancer.
Nurmi A; Mustonen H; Parviainen H; Peltola K; Haglund C; Seppänen H
Acta Oncol; 2018 Jun; 57(6):799-806. PubMed ID: 29241394
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant therapy is associated with a reduced lymph node ratio in patients with potentially resectable pancreatic cancer.
Roland CL; Yang AD; Katz MH; Chatterjee D; Wang H; Lin H; Vauthey JN; Pisters PW; Varadhachary GR; Wolff RA; Crane CH; Lee JE; Fleming JB
Ann Surg Oncol; 2015 Apr; 22(4):1168-75. PubMed ID: 25352267
[TBL] [Abstract][Full Text] [Related]
5. Vascular resection during pancreatectomy for pancreatic head cancer: A technical issue or a prognostic sign?
Belfiori G; Fiorentini G; Tamburrino D; Partelli S; Pagnanelli M; Gasparini G; Castoldi R; Balzano G; Rubini C; Zamboni G; Crippa S; Falconi M
Surgery; 2021 Feb; 169(2):403-410. PubMed ID: 32912782
[TBL] [Abstract][Full Text] [Related]
6. Outcomes after resection of locally advanced or borderline resectable pancreatic cancer after neoadjuvant therapy.
Barugola G; Partelli S; Crippa S; Capelli P; D'Onofrio M; Pederzoli P; Falconi M
Am J Surg; 2012 Feb; 203(2):132-9. PubMed ID: 21824596
[TBL] [Abstract][Full Text] [Related]
7. Survival benefit of neoadjuvant therapy in patients with non-metastatic pancreatic ductal adenocarcinoma: A propensity matching and intention-to-treat analysis.
Sugimoto M; Takahashi N; Farnell MB; Smyrk TC; Truty MJ; Nagorney DM; Smoot RL; Chari ST; Carter RE; Kendrick ML
J Surg Oncol; 2019 Nov; 120(6):976-984. PubMed ID: 31452208
[TBL] [Abstract][Full Text] [Related]
8. Clinical benefits of neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreatic head: an observational study using inverse probability of treatment weighting.
Fujii T; Satoi S; Yamada S; Murotani K; Yanagimoto H; Takami H; Yamamoto T; Kanda M; Yamaki S; Hirooka S; Kon M; Kodera Y
J Gastroenterol; 2017 Jan; 52(1):81-93. PubMed ID: 27169844
[TBL] [Abstract][Full Text] [Related]
9. A preoperative risk model for early recurrence after radical resection may facilitate initial treatment decisions concerning the use of neoadjuvant therapy for patients with pancreatic ductal adenocarcinoma.
Guo SW; Shen J; Gao JH; Shi XH; Gao SZ; Wang H; Li B; Yuan WL; Lin L; Jin G
Surgery; 2020 Dec; 168(6):1003-1014. PubMed ID: 32321665
[TBL] [Abstract][Full Text] [Related]
10. Effect of neoadjuvant radiotherapy on survival of non-metastatic pancreatic ductal adenocarcinoma: a SEER database analysis.
Wang D; Liu C; Zhou Y; Yan T; Li C; Yang Q; Xu Y; Zhao L; Pei Q; Tan F; Güngör C; Li Y
Radiat Oncol; 2020 May; 15(1):107. PubMed ID: 32404114
[TBL] [Abstract][Full Text] [Related]
11. Perioperative blood transfusions and survival in resected pancreatic adenocarcinoma patients given multimodality therapy.
Newhook TE; Prakash LR; Soliz J; Hancher-Hodges S; Speer BB; Wilks JA; Bruno ML; Dewhurst WL; Arvide EM; Maxwell JE; Ikoma N; Kim MP; Lee JE; Katz MHG; Tzeng CD
J Surg Oncol; 2021 Dec; 124(8):1381-1389. PubMed ID: 34398988
[TBL] [Abstract][Full Text] [Related]
12. Temporal Assessment of Prognostic Factors in Patients With Pancreatic Ductal Adenocarcinoma Undergoing Neoadjuvant Treatment and Resection.
Ren W; Xourafas D; Ashley SW; Clancy TE
J Surg Res; 2021 Jan; 257():605-615. PubMed ID: 32947122
[TBL] [Abstract][Full Text] [Related]
13. Poorly differentiated resectable pancreatic cancer: is upfront resection worthwhile?
Crippa S; Partelli S; Zamboni G; Barugola G; Capelli P; Inama M; Bassi C; Pederzoli P; Falconi M
Surgery; 2012 Sep; 152(3 Suppl 1):S112-9. PubMed ID: 22766365
[TBL] [Abstract][Full Text] [Related]
14. Use of neoadjuvant therapy in patients 75 years of age and older with pancreatic cancer.
Miura JT; Krepline AN; George B; Ritch PS; Erickson BA; Johnston FM; Oshima K; Christians KK; Evans DB; Tsai S
Surgery; 2015 Dec; 158(6):1545-55. PubMed ID: 26243342
[TBL] [Abstract][Full Text] [Related]
15. Overall survival is increased among stage III pancreatic adenocarcinoma patients receiving neoadjuvant chemotherapy compared to surgery first and adjuvant chemotherapy: An intention to treat analysis of the National Cancer Database.
Shubert CR; Bergquist JR; Groeschl RT; Habermann EB; Wilson PM; Truty MJ; Smoot RL; Kendrick ML; Nagorney DM; Farnell MB
Surgery; 2016 Oct; 160(4):1080-1096. PubMed ID: 27522556
[TBL] [Abstract][Full Text] [Related]
16. Reappraisal of Total Pancreatectomy in 45 Patients With Pancreatic Ductal Adenocarcinoma in the Modern Era Using Matched-Pairs Analysis: Multicenter Study Group of Pancreatobiliary Surgery in Japan.
Satoi S; Murakami Y; Motoi F; Sho M; Matsumoto I; Uemura K; Kawai M; Kurata M; Yanagimoto H; Yamamoto T; Mizuma M; Unno M; Kinoshita S; Akahori T; Shinzeki M; Fukumoto T; Hashimoto Y; Hirono S; Yamaue H; Honda G; Kwon M
Pancreas; 2016 Aug; 45(7):1003-9. PubMed ID: 26692442
[TBL] [Abstract][Full Text] [Related]
17. Risk of Venous Thromboembolism for Patients with Pancreatic Ductal Adenocarcinoma Undergoing Preoperative Chemotherapy Followed by Surgical Resection.
Boone BA; Zenati MS; Rieser C; Hamad A; Al-Abbas A; Zureikat AH; Hogg ME; Neal MD; Zeh HJ
Ann Surg Oncol; 2019 May; 26(5):1503-1511. PubMed ID: 30652227
[TBL] [Abstract][Full Text] [Related]
18. Outcomes after extended pancreatectomy in patients with borderline resectable and locally advanced pancreatic cancer.
Hartwig W; Gluth A; Hinz U; Koliogiannis D; Strobel O; Hackert T; Werner J; Büchler MW
Br J Surg; 2016 Nov; 103(12):1683-1694. PubMed ID: 27686238
[TBL] [Abstract][Full Text] [Related]
19. Survival of patients with borderline resectable pancreatic cancer who received neoadjuvant therapy and surgery.
Barnes CA; Chavez MI; Tsai S; Aldakkak M; George B; Ritch PS; Dua K; Clarke CN; Tolat P; Hagen C; Hall WA; Erickson BA; Evans DB; Christians KK
Surgery; 2019 Sep; 166(3):277-285. PubMed ID: 31272811
[TBL] [Abstract][Full Text] [Related]
20. Nodal downstaging as a treatment goal for node-positive pancreatic cancer.
Portuondo JI; Massarweh NN; Zhang Q; Chai CY; Tran Cao HS
Surgery; 2019 Jun; 165(6):1144-1150. PubMed ID: 30745009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
